Late-onset rheumatoid arthritis shows higher DAS28 scores and lower remission rates compared to young-onset disease in a meta-analysis.

This meta-analysis synthesized evidence regarding the clinical course of rheumatoid arthritis in patients with late-onset disease compared to those with young-onset disease. The study population included more than 5000 patients, encompassing individuals with late-onset rheumatoid arthritis defined as onset at 60 years or older and young-onset rheumatoid arthritis defined as onset before 60 years. The setting of the included studies was not reported in the source data. The analysis focused on the use of disease-modifying antirheumatic drugs, including conventional synthetic DMARDs, biologic agents, and targeted synthetic DMARDs, as the primary intervention exposure.

The primary outcome assessed was disease activity measured by DAS28 scores after treatment. The meta-analysis found that post-treatment DAS28 scores were higher in the late-onset group compared to the young-onset group. The mean difference was 0.26 with a 95% confidence interval of 0.11 to 0.41. This indicates a persistent difference in disease activity levels between the two age cohorts despite pharmacologic intervention.

Secondary outcomes included clinical remission rates and drug retention rates. Clinical remission achieved with biologic or targeted synthetic DMARDs was less frequent in the late-onset group than in the young-onset group. The relative risk was 0.36 with a 95% confidence interval of 0.16 to 0.79. Drug retention rates were equivalent between the two groups, with a hazard ratio of 0.98 and a 95% confidence interval of 0.87 to 1.11.

The study also utilized Mendelian randomization to assess causal relationships between genetically proxied plasma levels of soluble interleukin-6 receptor and tyrosine kinase 2 and rheumatoid arthritis risk. The analysis showed a reduced risk of RA associated with genetically elevated sIL6R, with an inverse variance weighted odds ratio of 0.92 and a 95% confidence interval of 0.87 to 0.98. The p-value for this association was 0.006. An inverse association was also noted for TYK2, though specific effect sizes and confidence intervals were not reported for this genetic marker.

Safety and tolerability data were not reported in the source meta-analysis. Adverse event rates, serious adverse events, discontinuations, and overall tolerability profiles were not detailed in the provided evidence. Consequently, clinicians cannot draw conclusions regarding the safety differences between age groups based on this specific synthesis.

Methodological limitations include the lack of reported settings for the underlying studies and the absence of specific safety data. The certainty of the evidence was not reported. Because the source is a meta-analysis and review rather than a primary trial, the results represent aggregated findings from multiple sources. The absence of reported funding or conflicts of interest limits the ability to fully assess potential biases.

These results imply that older adults with new-onset rheumatoid arthritis may experience higher disease activity and lower remission rates compared to younger patients when treated with similar biologic or targeted synthetic DMARD regimens. However, the lack of safety data means that treatment decisions must rely on general pharmacologic knowledge rather than age-specific safety profiles from this review. Further research is needed to clarify the mechanisms driving these differences in disease activity and remission.

Key questions remain unanswered regarding the optimal management strategies for late-onset rheumatoid arthritis. The inverse association between genetic markers and RA risk provides insight into disease etiology but does not directly inform clinical treatment protocols. Clinicians should interpret these findings with caution given the incomplete reporting of safety outcomes and the observational nature of the genetic association analysis.